Yashar Niknafs
 | This article is an autobiography or has been extensively edited by the subject or by someone connected to the subject. (September 2023) |
Yashar Niknafs | |
|---|---|
| Alma mater | Case Western Reserve University University of Michigan |
| Occupation(s) | CEO of LynxDx, Inc. |
| Scientific career | |
| Fields | Cellular and molecular biology, cancer genomics |
| Institutions | University of Michigan |
| Doctoral advisor | Arul Chinnaiyan |
Yashar Sharifi Niknafs is an American scientist, coder, and businessman. He currently serves as the chief executive officer of Lynx Dx, Inc.[1], one of the largest providers of COVID-19 PCR testing in the state of Michigan.[2]
Early life and education[edit]
Niknafs attended Stow-Munroe Falls High School in Akron, Ohio, where he was involved in theater and Science Olympiad.[3] He completed his undergraduate studies at Case Western Reserve University, earning a Bachelor's of Science in Biochemistry before moving to Ann Arbor, Michigan, where he received his PhD from the Cell and Molecular Biology Program at the University of Michigan under the mentorship of Arul Chinnaiyan.[4] His Ph.D. work focused mostly on bioinformatic analyses of next generation sequencing data for the purposes of better understanding the genome, delineating molecular mechanisms driving cancer, and discovering novel gene targets as biomarker candidates. He remained at the institution to complete a postdoctoral fellowship in cancer genomics and bioinformatics.
Career[edit]
The Chinnaiyan laboratory had previously identified the TMPRSS2-ERG (T2-ERG) gene fusion as a novel biomarker for prostate cancer.[5] Rather than continuing his medical school training, Niknafs took an extended leave-of-absence and co-founded LynxDx with Chinnaiyan and Jeffrey J Tosoian, a prominent urologic oncologist, with the intent to bring to market MyProstateScore, a pre-biopsy test using the T2-ERG, PCA3, and KLK3 biomarkers to detect clinically significant prostate cancer.[6] He also wrote the code for the company's proprietary laboratory information management system.
Following the onset of the COVID-19 pandemic, the company pivoted to providing PCR testing for detection of the virus, quickly becoming one of the largest providers of such testing in the state.[7] LynxDx provides weekly COVID-19 testing to the University of Michigan and to the Detroit Public Schools Community District.[8]
Publications[edit]
Partial list:
- Hosono Y, Niknafs YS, Prensner JR, Iyer MK, Dhanasekaran SM, Mehra R, Pitchiaya S, Tien J, Escara Wilke J, Poliakov A, Sankar K, Su F, Guo S, Freier SM, Bui H, Cao X, Malik R, Johnson TM, Beer DG, Feng FY, Zhou W, Chinnaiyan AM. Oncogenic Role of THOR, a Conserved Cancer/Testis Long Noncoding RNA. Cell. 2017.
- YS Niknafs, B. Pandian, T. Gajjar, Z. Gaudette, K. Wheelock, M.P. Maz, R.K. Achar, M. Song, C. Massaro, X. Cao, A.M. Chinnaiyan, MiPanda: A Resource for Analyzing and Visualizing Next-Generation Sequencing Transcriptomics Data, Neoplasia, 2018.
- Niknafs YS, Pandian B, Iyer HK, Chinnaiyan AM, Iyer MK. TACO produces robust multi-sample transcriptome assemblies from RNA-seq. Nature Methods. 2016.
- Niknafs YS, Han S, Ma T, Speers C, Zhang C, Wilder-Romans K, Iyer MK, Pitchiaya S, Malik R, Hosono Y, Prensner JR, Poliakov A, Singhal U, Xiao L, Kregel S, Siebenaler RF, Zhao SG, Uhl M, Gawronski A, Hayes DF, Pierce LJ, Cao X, Collins C, Backofen R, Sahinalp CS, Rae JM, Chinnaiyan AM, Feng FY. The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. Nature Communications. 2016.
- Shukla S, Zhang X, Niknafs YS, Xiao L, Mehra R, Cieślik M, Ross A, Schaeffer E, Malik B, Guo S, Freier SM, Bui HH, Siddiqui J, Jing X, Cao X, Dhanasekaran SM, Feng FY, Chinnaiyan AM, Malik R Identification and validation of PCAT14 as a prognostic biomarker in prostate cancer. Neoplasia. 2016.
- Iyer MK, Niknafs YS, Malik R, Singhal U, Sahu A, Hosono Y, Barrette TR, Prensner JR, Evans JR, Zhao S, Poliakov A, Cao X, Dhanasekaran SM, Wu Y-M, Robinson DR, Beer DG, Feng FY, Iyer HK, Chinnaiyan AM. The landscape of long noncoding RNAs in the human transcriptome. Nature Genetics. 2015 Jan 19.
References[edit]
- ^ Garber, Ken (August 2021). "The Headlong Growth of LynxDx". The Ann Arbor Observer. Retrieved 12 October 2021.
- ^ Haddad, Ken (24 May 2021). "Michigan COVID-19 testing average turnaround times by lab". Click On Detroit. Retrieved 12 October 2021.
- ^ Bejcek, Rachel (10 June 2007). "The Top 10 honor students - Class of 2007, Stow-Munroe Falls High School". My Town NEO. Retrieved 18 October 2021.
- ^ Karoub, Jeff (16 June 2020). "Yashar Niknafs: U-M alum launches startup, pivots from prostate diagnostics to COVID-19 testing". Michigan News. Retrieved 18 October 2021.
- ^ Tomlins SA, et al. (February 2008). "Role of the TMPRSS2–ERG Gene Fusion in Prostate Cancer". Neoplasia. 10 (2): 177–188. doi:10.1593/neo.07822. PMC 2244693. PMID 18283340.
- ^ Tosoian JJ, et al. (March 2021). "Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach". J Urol. 205 (3): 732–739. doi:10.1097/JU.0000000000001430. PMC 8189629. PMID 33080150.
- ^ Bruckner, Meredith (January 2021). "How an Ann Arbor company became a leading COVID testing lab in Michigan". All About Ann Arbor. Retrieved 15 October 2021.
- ^ Manes, Nick (May 2021). "Ann Arbor-based LynxDx finds growth in COVID testing contracts with schools". Crain's Detroit Business. Retrieved 15 October 2021.